X
<

Dentsply Sirona Reported Disappointing 2Q17 Results

PART:
1 2 3 4 5 6
Part 6
Dentsply Sirona Reported Disappointing 2Q17 Results PART 6 OF 6

Discussing Dentsply Sirona’s Recent Stock Performance

Stock performance

Dentsply Sirona (XRAY) closed at $55.30 on August 11, 2017. The company was trading at its 52-week low of $54.50 on the day. On that day, Dentsply Sirona stock closed ~16% below its 52-week high of $65.68 on May 8, 2017.

XRAY has a 50-day moving average of $62.88 and a 200-day moving average of $62.38. The stock is on a bearish trend. Year-to-date, Dentsply Sirona stock has fallen ~4.5% and over the last month, the stock has fallen ~15%.

Discussing Dentsply Sirona’s Recent Stock Performance

Interested in ALGN? Don't miss the next report.

Receive e-mail alerts for new research on ALGN

Success! You are now receiving e-mail alerts for new research. A temporary password for your new Market Realist account has been sent to your e-mail address.

Success! has been added to your Ticker Alerts.

Success! has been added to your Ticker Alerts. Subscriptions can be managed in your user profile.

Dentsply Sirona stock fell ~8.4% following the company’s 2Q17 earnings results on August 9, 2017, as the company failed to meet analysts’ estimates for the quarter. Further, Dentsply Sirona made a downward revision to its 2017 guidance. The company’s stock price has declined further in the days following the 2Q17 earnings release, impacted by the weak investor sentiment.

XRAY stock is estimated to be oversold by some analysts and is estimated to grow over the long term. The company’s short-term performance is expected to be volatile as it struggles with some major near-term challenges.

Industry comparison

Dentsply Sirona (XRAY) has declined ~9.6% in the past 12 months. As represented by the S&P 500, the market returned ~12.8% during the same period. We can also compare Dentsply Sirona’s performance with the broader US healthcare sector, as represented by the Health Care Select Sector SPDR ETF (XLV). XLV has returned more than 5.8% in the past year.

On August 14, 2017, peers Integra LifeSciences (IART), Zimmer Biomet Holdings (ZBH), and Align Technology (ALGN) generated returns of -24%, 10%, and 43%, respectively, over the past 12 months.

X

Please select a profession that best describes you: